With more study results at their fingertips the FDA has news for multiple sclerosis patients taking Aubagio. Clinically Isolated Syndrome or CIS “is defined as a first clinical event with one or more symptoms suggestive of MS, but without sufficient evidence to meet the diagnostic criteria for MS.” (ms-collition.org) It seems Aubagio can reduce the risk of a second relapse for CIS patients.  The TOWER study of 1,169 people with RRMS for 48 weeks. Aubagio is 36.3% effective at reducing relapses compared to the placebo group at the dosage of 14 mg with a reduction in disability progression by 31.5%. Patients taking the 7 mg dose were found to have a relapse reduction rate of only 22.3% and no change in disability progression compared to the placebo.

Oh, and for those following my hair loss saga with Tecfidera, only 13% of Aubagio patients lose hair and then only for six months! Further information on the updates to Aubagio can be found at: www.ms-collition.org. Image from: www.empr.com.